Exagen Diagnostics Obtains $25,000,000 New Funding

  • Feed Type
  • Date
    11/4/2013
  • Company Name
    Exagen Diagnostics
  • Mailing Address
    1261 Liberty Way Vista, CA 92081
  • Company Description
    Exagen Diagnostics Inc. discovers, validates and commercializes small sets of genomic markers, providing prognostic reagents for commercial laboratory testing and for pharmaceutical use in clinical trials. In leading the development of a new class of prognostic testing options, Exagen is working to create panels of tests that define a new standard of accuracy and performance.
  • Website
    http://www.exagen.com
  • Transaction Type
    Debt
  • Transaction Amount
    $25,000,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    Exagen intends to use the proceeds to grow its U.S. sales force to 25 – 30 representatives, fueling already strong revenue growth in SLE+ as well as the company’s pipeline of rheumatology tests.
  • M&A Terms
  • Venture Investor
    Capital Royalty